Published in Radiother Oncol on February 01, 2004
RapidArc, SmartArc and TomoHD compared with classical step and shoot and sliding window intensity modulated radiotherapy in an oropharyngeal cancer treatment plan comparison. Radiat Oncol (2013) 1.08
Eight years of IMRT quality assurance with ionization chambers and film dosimetry: experience of the Montpellier Comprehensive Cancer Center. Radiat Oncol (2011) 0.90
Intensity-modulated radiotherapy in patients with head and neck cancer: a European single-centre experience. Br J Radiol (2011) 0.89
Comparison of survival rates between patients treated with conventional radiotherapy and helical tomotherapy for head and neck cancer. Radiat Oncol J (2013) 0.88
Feasibility of intensity-modulated and image-guided radiotherapy for functional organ preservation in locally advanced laryngeal cancer. PLoS One (2012) 0.85
The potential of helical tomotherapy in the treatment of head and neck cancer. Oncologist (2013) 0.84
Improving target dose coverage and organ-at-risk sparing in intensity-modulated radiotherapy of advanced laryngeal cancer by a simple optimization technique. Br J Radiol (2014) 0.82
Proof of principle of ocular sparing in dogs with sinonasal tumors treated with intensity-modulated radiation therapy. Vet Radiol Ultrasound (2010) 0.79
Helical tomotherapy in head and neck cancer: a European single-center experience. Oncologist (2015) 0.75
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol (2011) 7.46
Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med (2012) 4.59
A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res (2006) 2.35
A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res (2008) 2.18
The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther (2009) 2.14
Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol (2011) 1.82
Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther (2008) 1.78
Stereotactic body radiotherapy for oligometastases. Lancet Oncol (2013) 1.76
Reovirus activates human dendritic cells to promote innate antitumor immunity. J Immunol (2008) 1.70
Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res (2012) 1.67
Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin Cancer Res (2010) 1.63
Assessment and management of dysphagia in patients with head and neck cancer who receive radiotherapy in the United Kingdom - a web-based survey. Oral Oncol (2011) 1.58
Making sense of post-treatment surveillance in head and neck cancer: when and what of follow-up. Cancer Treat Rev (2009) 1.58
Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. Clin Cancer Res (2008) 1.56
Weekly volume and dosimetric changes during chemoradiotherapy with intensity-modulated radiation therapy for head and neck cancer: a prospective observational study. Int J Radiat Oncol Biol Phys (2010) 1.55
Intensity-modulated radiotherapy in patients with locally advanced rectal cancer reduces volume of bowel treated to high dose levels. Int J Radiat Oncol Biol Phys (2006) 1.53
REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res (2010) 1.53
Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. Clin Cancer Res (2009) 1.50
99mTc-sestamibi imaging in the assessment of toremifene as a modulator of multidrug resistance in patients with breast cancer. J Nucl Med (2002) 1.44
Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res (2008) 1.44
Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion. Cancer Res (2002) 1.42
Should the treatment paradigms for oral and oropharyngeal cancers be changed now: the role of human papilloma virus? ANZ J Surg (2011) 1.40
Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin Cancer Res (2010) 1.35
Biological significance of c-erbB family oncogenes in head and neck cancer. Cancer Metastasis Rev (2005) 1.31
Targeting HOX and PBX transcription factors in ovarian cancer. BMC Cancer (2010) 1.29
Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus. J Immunol (2009) 1.25
Dosimetry audit for a multi-centre IMRT head and neck trial. Radiother Oncol (2009) 1.20
Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. BMC Cancer (2011) 1.17
Dose-volume constraints to reduce rectal side effects from prostate radiotherapy: evidence from MRC RT01 Trial ISRCTN 47772397. Int J Radiat Oncol Biol Phys (2009) 1.16
Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells. Cancer Res (2002) 1.13
Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization. Clin Cancer Res (2011) 1.12
The impact of introducing intensity modulated radiotherapy into routine clinical practice. Radiother Oncol (2005) 1.10
Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway. BMC Cancer (2012) 1.09
Head and neck cancer in the elderly: an overview on the treatment modalities. Cancer Treat Rev (2008) 1.08
Key molecular mechanisms in lung cancer invasion and metastasis: a comprehensive review. Crit Rev Oncol Hematol (2013) 1.05
Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples. Mod Pathol (2012) 1.03
Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol (2009) 1.02
Validation of the Sydney Swallow Questionnaire (SSQ) in a cohort of head and neck cancer patients. Oral Oncol (2010) 0.99
The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage. PLoS One (2012) 0.98
Intensity Modulated Radiotherapy (IMRT) in locally advanced thyroid cancer: acute toxicity results of a phase I study. Radiother Oncol (2007) 0.98
Targeting the HOX/PBX dimer in breast cancer. Breast Cancer Res Treat (2012) 0.97
Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck. J Pathol (2009) 0.97
Comprehensive review of small bowel metastasis from head and neck squamous cell carcinoma. Oral Oncol (2010) 0.97
Dosimetric explanations of fatigue in head and neck radiotherapy: an analysis from the PARSPORT Phase III trial. Radiother Oncol (2012) 0.97
Implications of understanding cancer stem cell (CSC) biology in head and neck squamous cell cancer. Oral Oncol (2011) 0.96
Assessment of a customised immobilisation system for head and neck IMRT using electronic portal imaging. Radiother Oncol (2005) 0.96
Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells. Int J Cancer (2012) 0.95
The value of magnetic resonance imaging in target volume delineation of base of tongue tumours--a study using flexible surface coils. Radiother Oncol (2010) 0.94
A modified inflammatory bowel disease questionnaire and the Vaizey Incontinence questionnaire are more sensitive measures of acute gastrointestinal toxicity during pelvic radiotherapy than RTOG grading. Int J Radiat Oncol Biol Phys (2006) 0.94
Swallowing outcomes following Intensity Modulated Radiation Therapy (IMRT) for head & neck cancer - a systematic review. Oral Oncol (2010) 0.94
Novel targeted radiosensitisers in cancer treatment. Curr Drug Discov Technol (2009) 0.93
Dose-response analysis of parotid gland function: what is the best measure of xerostomia? Radiother Oncol (2013) 0.93
Correlation between dose to the pharyngeal constrictors and patient quality of life and late dysphagia following chemo-IMRT for head and neck cancer. Radiother Oncol (2009) 0.93
Targeted radiosensitization by the Chk1 inhibitor SAR-020106. Int J Radiat Oncol Biol Phys (2012) 0.93
Quality of life and outcomes research in head and neck cancer: a review of the state of the discipline and likely future directions. Cancer Treat Rev (2009) 0.92
Tracheo-oesophageal party wall thickness in laryngectomised patients in India: implications for surgical voice restoration. J Surg Oncol (2010) 0.92
A phase I study of dose-escalated chemoradiation with accelerated intensity modulated radiotherapy in locally advanced head and neck cancer. Radiother Oncol (2007) 0.92
Oncolytic viruses in radiation oncology. Radiother Oncol (2011) 0.92
Immunotherapeutic potential of oncolytic virotherapy. Lancet Oncol (2008) 0.92
Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy. Expert Rev Anticancer Ther (2015) 0.92
Assessment of the Na/I symporter as a reporter gene to visualize oncolytic adenovirus propagation in peritoneal tumours. Eur J Nucl Med Mol Imaging (2010) 0.92
Implementing the UK Medical Research Council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. Radiother Oncol (2004) 0.91
Reducing the risk of xerostomia and mandibular osteoradionecrosis: the potential benefits of intensity modulated radiotherapy in advanced oral cavity carcinoma. Med Dosim (2008) 0.91
Dose-escalated intensity-modulated radiotherapy is feasible and may improve locoregional control and laryngeal preservation in laryngo-hypopharyngeal cancers. Int J Radiat Oncol Biol Phys (2011) 0.90
Interactions between ionizing radiation and drugs in head and neck cancer: how can we maximize the therapeutic index? Curr Opin Investig Drugs (2002) 0.90
The phosphoinositide 3-kinase signalling pathway as a therapeutic target in squamous cell carcinoma of the head and neck. Expert Opin Ther Targets (2005) 0.90
Changes in functional imaging parameters following induction chemotherapy have important implications for individualised patient-based treatment regimens for advanced head and neck cancer. Radiother Oncol (2012) 0.90
Electroglottographic comparison of voice outcomes in patients with advanced laryngopharyngeal cancer treated by chemoradiotherapy or total laryngectomy. Int J Radiat Oncol Biol Phys (2007) 0.90
Targeting HOX transcription factors in prostate cancer. BMC Urol (2014) 0.89
Novel approaches to improve the therapeutic index of head and neck radiotherapy: an analysis of data from the PARSPORT randomised phase III trial. Radiother Oncol (2012) 0.89
Clinical significance of heat shock protein-70 expression in bladder cancer. Urology (2003) 0.89